EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Harnessing Cuproptosis for Antitumor Immunity: A Review of Current Evidence and Therapeutic Strategies

Ivan Lu iD, Jin Zhang, Xinbin Chen, Xiao-Jing Wang

Molecular Carcinogenesis · 2026

DOI: 10.1002/mc.70128 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Carcinogenesis, 2026. Verfasst von Ivan Lu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, and Department of Otolaryngology, University of California, Davis, Sacramento, California, USA. Hauptthemen laut MEDLINE: Cuproptosis, Neoplasms, Copper. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 126 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: BLRD VA, NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICI) have transformed cancer therapy, yet patient response rates remain low across most tumor types, underscoring the need for strategies that enhance tumor immunogenicity. Cuproptosis, a recently characterized form of regulated cell death driven by intracellular copper accumulation and lipoylated protein aggregation, has emerged as a mechanistically distinct pathway with immunological implications that remain largely unexplored. In this review, we examine the evidence supporting cuproptosis as an inducer of immunogenic cell death, including its capacity to trigger damage‐associated molecular patterns, promote dendritic cell maturation, and remodel the immunosuppressive tumor microenvironment. The two principal copper ionophores, elesclomol and disulfiram, are discussed in the context of mechanistic studies and therapeutic relevance. We identify key mechanistic gaps and propose cuproptosis‐based combination strategies as a rational approach to expanding the ICI responsive patient population. Preclinical and clinical data across major cancer types are evaluated to identify the therapeutic relevance of cuproptosis. Through addressing these points, we conclude that cuproptosis is an under‐appreciated route for improving existing immunotherapies for cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CuproptosisNeoplasmsCopperHumansAnimalsTumor MicroenvironmentImmunotherapyImmunogenic Cell DeathImmune Checkpoint Inhibitors

Stichwörter der Autor:innen

antitumor immunitycancer immunotherapycuproptosisimmunogenic cell deathtumor microenvironment

Substanzen

CopperImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Pathology and Laboratory Medicine, and Department of Otolaryngology, University of California, Davis, Sacramento, California, USA.
  • Department of Surgical and Radiological Sciences, University of California, Davis, Davis, California, USA.
  • VA Northern California Health Care System, Sacramento, California, USA.

ORCID-Profile: Ivan Lu

Förderung

  • BLRD VA
  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Lu, I., Zhang, J., Chen, X., & Wang, X. J. (2026). Harnessing Cuproptosis for Antitumor Immunity: A Review of Current Evidence and Therapeutic Strategies. Molecular Carcinogenesis. https://doi.org/10.1002/mc.70128

Vancouver

Lu I, Zhang J, Chen X, Wang XJ. Harnessing Cuproptosis for Antitumor Immunity: A Review of Current Evidence and Therapeutic Strategies. Molecular Carcinogenesis. 2026. doi:10.1002/mc.70128

BibTeX
@article{Lu2026,
  author = {Lu, Ivan and Zhang, Jin and Chen, Xinbin and Wang, Xiao-Jing},
  title = {Harnessing Cuproptosis for Antitumor Immunity: A Review of Current Evidence and Therapeutic Strategies},
  journal = {Molecular Carcinogenesis},
  year = {2026},
  doi = {10.1002/mc.70128}
}
Kostenlos starten →